Setara Biosciences officially entered the biotechnology landscape on Friday, announcing a $90 million Series A financing round designed to propel its portfolio of precision medicines into advanced clinical stages. The San Diego-based startup emerged as a strategic spin-off following the high-profile acquisition of Actio Biosciences by Jazz Pharmaceuticals earlier this year. With a primary focus on rare neuromuscular disorders and broader expansion indications, Setara aims to leverage a specialized human genetics platform to address significant unmet medical needs. The financing round was led by a syndicate of prominent life sciences investors, including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures, with Jazz Pharmaceuticals also participating as a new strategic investor.
The inception of Setara Biosciences marks the latest chapter in a rapidly evolving narrative for the original Actio Biosciences team. In August 2023, Jazz Pharmaceuticals entered into a definitive agreement to acquire Actio for an upfront payment of $820 million, with an additional $500 million potentially due upon the achievement of specific regulatory and commercial milestones. The centerpiece of that acquisition was ABS-1230, a potent small molecule inhibitor of KCNT1 ion channels intended to treat KCNT1-related epilepsy. While Jazz integrated the epilepsy program into its own neuroscience pipeline, the remaining assets—focused on diverse genetic targets—were earmarked for a new, independent entity. This entity, now known as Setara Biosciences, is led by David Goldstein, the former CEO of Actio, who serves as the company’s president and executive chair.
The Strategic Transition from Actio to Setara
The transition from Actio to Setara represents a sophisticated "hub-and-spoke" model of biotechnology development. By spinning off the non-epilepsy assets, the founding team and its investors have created a vehicle to maximize the value of a discovery platform that utilizes human genetics to identify high-probability drug targets. Actio’s core philosophy was rooted in the belief that understanding rare genetic mutations can provide a roadmap for treating both orphan diseases and more prevalent conditions that share similar biological pathways.
Setara’s launch capital of $90 million provides a substantial runway to advance its lead candidate, STAR-0871, while simultaneously exploring discovery-stage programs in migraine and other neurological conditions. The involvement of original Actio backers in this new Series A round signals continued confidence in the underlying science and the leadership team’s ability to execute clinical milestones.
STAR-0871: A Precision Approach to TRPV4 Inhibition
The flagship program in Setara’s pipeline is STAR-0871, formerly known as ABS-0871. This therapeutic is a small molecule inhibitor designed to target TRPV4 (Transient Receptor Potential Vanilloid 4), an ion channel protein that plays a critical role in regulating the flow of calcium ions across cell membranes. TRPV4 is expressed in various tissues, including the peripheral nervous system, the bladder, and the lungs. When this channel becomes overactive due to genetic mutations or other physiological triggers, it can lead to severe cellular dysfunction and tissue damage.
Setara is currently evaluating STAR-0871 for two distinct indications: a rare neuromuscular disorder and a common urological condition. This dual-track strategy is designed to mitigate the risks associated with orphan drug development while tapping into large-scale commercial markets.
Addressing Charcot-Marie-Tooth Disease Type 2C
The primary rare disease target for STAR-0871 is Charcot-Marie-Tooth disease type 2C (CMT2C). CMT2C is an autosomal dominant axonal neuropathy caused by "gain-of-function" mutations in the TRPV4 gene. These mutations result in a hyperactive ion channel that allows an excessive influx of calcium into peripheral nerves, leading to progressive nerve degeneration, muscle weakness, and sensory loss.
Patients with CMT2C often experience severe symptoms beginning in childhood or early adulthood, including vocal cord paralysis, respiratory muscle weakness, and difficulty walking. Currently, there are no therapies approved by the U.S. Food and Drug Administration (FDA) that address the underlying genetic cause of CMT2C. Treatment is limited to supportive care, such as physical therapy and orthotics. Setara’s approach aims to selectively inhibit the overactive TRPV4 channels, thereby normalizing calcium levels and halting or reversing the progression of nerve damage.
Expansion into Overactive Bladder (OAB)
While CMT2C represents a critical unmet need in the rare disease space, Setara is also positioning STAR-0871 as a potential breakthrough for overactive bladder (OAB). The TRPV4 channel is known to play a key role in the mechanosensation of the bladder wall; specifically, it helps the body detect bladder fullness. In many patients with OAB, the bladder becomes hyper-responsive, leading to symptoms of urgency, frequency, and nocturia.
OAB affects an estimated 33 million adults in the United States alone. Despite its prevalence, current treatment options—which primarily include antimuscarinics and beta-3 adrenergic agonists—often suffer from limited efficacy or bothersome side effects like dry mouth and constipation, leading to high discontinuation rates among patients. By targeting the sensory mechanism of the bladder through TRPV4 inhibition, Setara hopes to provide a more effective and better-tolerated alternative for this massive patient population.
Clinical Progress and Future Milestones
The clinical development of STAR-0871 is already well underway. At the time of the Jazz acquisition in August, a Phase 1 trial was evaluating the safety and pharmacokinetics of the drug in healthy volunteers. Setara has recently confirmed that the healthy volunteer portion of this study is complete, providing a foundation of safety data that supports further testing in patient populations.
The company has outlined an ambitious timeline for 2025. Setara plans to initiate a Phase 1b clinical trial specifically enrolling patients with CMT2C to assess the drug’s impact on disease biomarkers and clinical symptoms. Parallel to this effort, the company intends to launch a Phase 2a trial in patients with overactive bladder. This dual clinical path will allow Setara to gather proof-of-concept data in both a genetically defined orphan population and a broader clinical indication simultaneously.
Beyond STAR-0871, Setara’s pipeline includes several undisclosed discovery-stage programs. These programs are focused on targets identified through the company’s genetics platform and are expected to address various forms of epilepsy and migraine. The ability to maintain these early-stage assets within Setara ensures that the company remains a robust discovery engine even as its lead program moves deeper into the clinic.
Financial and Industry Context
The $90 million Series A round for Setara comes at a time of cautious optimism in the biotech venture capital market. While the "mega-rounds" of 2021 have become less frequent, investors remain highly interested in companies with de-risked clinical assets and clear pathways to regulatory approval. Setara’s origin story—spinning off from a successful $800 million-plus acquisition—provides it with a level of institutional pedigree that is rare for a "new" startup.
The participation of Jazz Pharmaceuticals as an investor is particularly noteworthy. It suggests a continued interest from the mid-cap pharma giant in the work being done by the former Actio team. For Jazz, this investment serves as a strategic hedge, allowing them to maintain a "seat at the table" for Setara’s future developments without the immediate burden of full ownership.
Analysis of the Precision Medicine Strategy
Setara’s strategy reflects a broader trend in the pharmaceutical industry: the shift toward precision medicine. By identifying specific ion channel dysfunctions through human genetics, the company is moving away from the "one-size-fits-all" approach that has dominated neuroscience and urology for decades.
In the case of CMT2C, the genetic driver is well-understood, making it an ideal candidate for a precision small-molecule approach. If Setara can demonstrate that STAR-0871 successfully modulates the TRPV4 channel in humans, it will validate not only the drug but also the entire platform used to discover it. Furthermore, the expansion into OAB demonstrates how rare disease research can serve as a "proving ground" for treatments that eventually scale to reach millions.
David Goldstein, President and Executive Chair of Setara, emphasized this vision in a statement accompanying the launch. "Setara allows us to take the next step in our journey, to carry forward a pipeline of promising programs for rare diseases, with the potential to ultimately reach much broader patient populations," Goldstein noted. This sentiment underscores the company’s dual mission of serving neglected patient communities while pursuing significant commercial opportunities.
Chronology of Key Events
The path to Setara’s launch involved several pivotal moments over the last three years:
- 2021-2022: Actio Biosciences establishes its human genetics platform and identifies several ion channel targets, including KCNT1 and TRPV4.
- Early 2023: Actio advances ABS-1230 into clinical readiness for KCNT1-related epilepsy and progresses ABS-0871 (now STAR-0871) into Phase 1 testing.
- August 2024: Jazz Pharmaceuticals announces the acquisition of Actio Biosciences for $820 million upfront to secure the KCNT1 program.
- September 2024: The acquisition officially closes. Assets not related to the KCNT1 program are prepared for spin-off.
- October 2024: Setara Biosciences officially launches with a $90 million Series A round, led by original Actio investors and Jazz Pharmaceuticals.
- 2025 (Projected): Commencement of Phase 1b trials for CMT2C and Phase 2a trials for Overactive Bladder.
Conclusion and Market Outlook
As Setara Biosciences begins its independent operations, it stands as a testament to the efficiency of modern biotech deal-making. By separating the KCNT1 epilepsy program from the rest of the portfolio, the founders and investors have ensured that every asset in the original Actio pipeline has a dedicated path to the clinic.
The success of Setara will likely depend on the upcoming Phase 1b and Phase 2a data for STAR-0871. If the drug proves effective in CMT2C, it will offer the first disease-modifying therapy for a devastating rare condition. If it simultaneously proves effective in overactive bladder, Setara could become one of the most valuable private companies in the neurology and urology sectors. With $90 million in the bank and a leadership team that has already proven its ability to deliver a massive exit, Setara Biosciences is positioned as a significant player to watch in the precision medicine arena.
